<DOC>
	<DOC>NCT02542410</DOC>
	<brief_summary>The proposed pilot study will estimate the efficacy and safety of a novel therapeutic agent, cabergoline, with a clinical standard therapy, norethindrone acetate, for the treatment of endometriosis-associated pain in young women with endometriosis.</brief_summary>
	<brief_title>Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<criteria>Surgically confirmed endometriosis Age between 1835 y, and premenopausal Pelvic pain score â‰¥3 on a Visual Analog Scaleover the last month Use of other concurrent hormone medications (such as birth control pills) Impaired liver function (ALT &gt; 2x normal) or liver disease (cirrhosis, hepatitis) Pregnancy Breast cancer Active thromboembolic disease Uncontrolled hypertension, history of cardiac valve disorder, history of fibrotic disorders</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>